Home › Funds › Cinctive Capital Management LP › APGE
Cinctive Capital Management LP position in APGE
APOGEE THERAPEUTICS INC
Cinctive Capital Management LP reported holding 350,165 shares of APGE (APOGEE THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$46.5M, representing 1.73% of its reported portfolio and ranking #4 among its reported holdings. Cinctive Capital Management LP has disclosed APGE holdings in 3 of the last 10 reported quarters, going back to Q1 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Cinctive Capital Management LP's APGE position evolved
Cinctive Capital Management LP first disclosed a stake in APGE in Q1 2024 at 23,229 shares (US$1.5M). The position peaked in Q2 2026 at 350,165 shares, worth US$46.5M. Across 3 filings, Cinctive Capital Management LP held the position steady without any share-count change. The most recent filing (Q2 2026) shows 350,165 shares valued at US$46.5M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 23.23K | $1.54M | New |
| Q4 2025 | 33.26K | $2.51M | New |
| Q2 2026 | 350.17K | $46.48M | New |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About APGE and 13F data
APGE (APOGEE THERAPEUTICS INC) is a company whose sector is not yet classified in our data. 59 other funds we track also report a position in APGE — the largest reported positions include Venrock Adviser, LLC (US$1.13B), HBK INVESTMENTS L P (US$378.3M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$231.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding APGE
- Venrock Adviser, LLC 8.49M sh · $1.13B · Q2 2026
- HBK INVESTMENTS L P 2.85M sh · $378.28M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 1.74M sh · $230.96M · Q2 2026
- GLAZER CAPITAL, LLC 1.64M sh · $217.82M · Q2 2026
- Paradigm Biocapital Advisors LP 1.58M sh · $209.23M · Q2 2026
- Pentwater Capital Management LP 1.43M sh · $189.14M · Q2 2026
- PERCEPTIVE ADVISORS LLC 1.31M sh · $173.63M · Q2 2026
- Affinity Asset Advisors, LLC 987.00K sh · $131.00M · Q2 2026
- First Light Asset Management, LLC 930.29K sh · $123.48M · Q2 2026
- Kryger Capital LLC 742.55K sh · $98.56M · Q2 2026
- First Trust Capital Management L.P. 625.18K sh · $82.98M · Q2 2026
- Remedium Capital Partners, LLC 586.69K sh · $77.87M · Q2 2026
More on Cinctive Capital Management LP
FAQ
How long has Cinctive Capital Management LP held APGE?
Cinctive Capital Management LP has disclosed APGE holdings in 3 of the last 10 reported quarters, going back to Q1 2024.
What is Cinctive Capital Management LP's current position in APGE?
As of Q2 2026, Cinctive Capital Management LP holds 350.17K shares of APGE (APOGEE THERAPEUTICS INC), valued at $46.48M, representing 1.73% of its reported portfolio and ranking #4.
Has Cinctive Capital Management LP been buying or selling APGE?
In the latest 13F filing (Q2 2026), Cinctive Capital Management LP newly opened its position in APGE. The position peaked in Q2 2026 at 350.17K shares.
Which other funds hold APGE?
Other major institutional holders of APGE include Venrock Adviser, LLC, HBK INVESTMENTS L P, DRIEHAUS CAPITAL MANAGEMENT LLC, among 59 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.